摘要
目的:探讨视网膜母细胞瘤瘤组织中铁蛋白(FER)的分布、表达与肿瘤的临床及预后的关系以及作为肿瘤标记物的价值。方法:采用免疫组化方法观察视网膜母细胞瘤组织30例中FER的阳性分布。结果:FER阳性率96.6%(29/30),就诊年龄<2岁者,FER阳性范围以+++为主,占71.4%(5/7),阳性强度以++为主,占71.4%(5/7),就诊年龄>7岁者,阳性范围以+++为主,占83.3%(5/6),而就诊年龄在2～7岁之间者,阳性范围及强度均显示+为主(P<0.05);青光眼期患者,阳性范围以+++为主,占58.3%(7/12),眼内期++为主,占42.9%(3/7),眼外蔓延期+为主,占45.6%(5/11,P<0.05);分化型视网膜母细胞瘤阳性强度++为主,占85.7%(6/7),未分化型+为主,占65.2%(15/23,P<0.01)。结论:视网膜母细胞瘤中FER免疫组化的高表达可能是较好预后的一个临床病理指征。
AIM: To assess the frequency of ferritin presence in retinoblastomas and its value as a tumor marker; to determine whether the ferritin expression is related to retinoblastoma associated characteristics. · METHODS: Thirty specimens with retinoblastoma were examined by using immunohi stochemical technique. · RESULTS: The positive frequency of ferritin immunostain was 96.6% (29/30). In patients younger than 2 years old, the distribution of ferritin immunostain sho wed +++ in 71.4% (5/7) and intensity ++ in 71.4% (5/7); in patients older than 7 years old, the distribution of ferritin immunostain showed +++ in 83.3% (5/6), whereas in patients aged between 2 and 7 years old, both the distribution and th e intensity of ferritin immunostain showed + predominantly (P <0.05). The ferrit in antibody showed as the following: +++ immunostain in 58.3% (7/12) in patients at the glaucoma stage, ++ in 42.9% (3/7) in thoseat the intraocular stage and + 45.6% (5/11) in those at the extraocular extension stage (P <0.005). The intens ity of ferritin immunostain showed ++ in 85.7% (6/7) in differentiated retinobla stoma, but + in 65.2(15/23) in undifferentiated retinoblastoma (P < 0.01). · CONCLUSION: Immunohistochemical demonstration of high ferritin expression in retinoblastoma may be a clinic-pathologic indication for better prognosis. ·
出处
《国际眼科杂志》
CAS
2004年第6期1028-1030,共3页
International Eye Science
